Psoriasis: Dysregulation of innate immunity

British Journal of Dermatology

Volumn 152, Issue 6, 2005, Pages 1098-1107

  Bos, J D ^a   De Rie, M A ^a   Teunissen, M B M ^a   Piskin, G ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

Cytokine production; NK T cell; Specific immunity; T cell activation; Type 1 T cell

Indexed keywords

ADALIMUMAB; CERTOLIZUMAB PEGOL; CYTOKINE; ETANERCEPT; GAMMA INTERFERON; INFLIXIMAB; ONERCEPT; PEGSUNERCEPT; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR 1; UNCLASSIFIED DRUG;

BIOLOGICAL THERAPY; CHRONIC INFLAMMATION; CYTOKINE PRODUCTION; DENDRITIC CELL; GENOMICS; HUMAN; IMMUNOPATHOGENESIS; INNATE IMMUNITY; KERATINOCYTE; LYMPHOCYTE MIGRATION; NATURAL KILLER CELL; NEUTROPHIL; NONHUMAN; PRIORITY JOURNAL; PSORIASIS; REVIEW; SIGNAL TRANSDUCTION; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION;

ANTIGENS; DENDRITIC CELLS; GENETIC PREDISPOSITION TO DISEASE; HUMANS; IMMUNITY, NATURAL; IMMUNOLOGIC MEMORY; KERATINOCYTES; KILLER CELLS, NATURAL; LYMPHOCYTE ACTIVATION; MODELS, IMMUNOLOGICAL; POLYMORPHISM, GENETIC; PSORIASIS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 21644455704     PISSN: 00070963     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2005.06645.x     Document Type: Review

References (67)

1. Krueger JG. The immunologic basis for the treatment of psoriasis with new biologic agents. J Am Acad Dermatol 2002; 46:1-23.
2. Gottlieb AB, Bos JD. Recombinantly engineered human proteins: transforming the treatment of psoriasis. Clin Immunol 2002; 105:105-16.
3. Griffiths CE. Immunotherapy for psoriasis: from serendipity to selectivity. Lancet 2002; 359:279-80.
4. De Rie MA, Bos JD. Biologicals for the treatment of immune mediated skin disease. In: Skin Immune System: Cutaneous Immunology and Clinical Immunodermatology (Bos JD, ed.), 3rd edn. Boca Raton, FL: CRC Press, 2005; 789-804.
5. Schottelius AJG, Moldawer LL, Dinarello ChA et al. Biology of tumor necrosis factor-α-implications for psoriasis. Exp Dermatol 2004; 13:193-222.
6. Goedkoop AY, Kraan MC, Teunissen MBM et al. Early effects of TNF-alpha blockade on skin and synovial tissue in patients with active psoriasis and psoriatic arthritis. Ann Rheum Dis 2004; 63:769-73.
7. Nickoloff BJ. Skin innate immune system in psoriasis: friend or foe? J Clin Invest 1999; 104:1181-9.
8. Nickoloff BJ, Schröder JM, von den Driesch P et al. Is psoriasis a T-cell disease? Exp Dermatol 2000; 9:359-75.
9. Bos JD. Skin Immune System: Cutaneous Immunology and Clinical Immunodermatology (Bos JD, ed.), 3rd edn. Boca Raton, FL: CRC Press, 2005.
10. Bos JD, De Rie MA. The pathogenesis of psoriasis: immunological facts and speculations. Immunol Today 1999; 20:40-6.
11. Lew W, Bowcock AM, Krueger JG. Psoriasis vulgaris: cutaneous lymphoid tissue supports T-cell activation and 'type 1' inflammatory gene expression. Trends Immunol 2004; 25:295-305.
12. Piskin G, Sylva-Steenland RMR, Bos JD, Teunissen MBM. T cells in psoriatic lesional skin that survive conventional therapy with NB-UVB radiation display reduced IFN-γ expression. Arch Dermatol Res 2004; 295:509-16.
13. Beutner EH (ed.). Autoimmunity in Psoriasis. Boca Raton, FL: CRC Press, 1982.
14. Majewski S, Jablonska S. Possible involvement of epidermodysplasia verruciformis human papillomaviruses in the immunopathogenesis of psoriasis: a proposed hypothesis. Exp Dermatol 2003; 12:721-8.
15. Gudjonsson JE, Thorarinsson AM, Sigurgeirsson B et al. Streptococcal throat infections and exacerbation of chronic plaque psoriasis: a prospective study. Br J Dermatol 2003; 149:530-4.
16. Gudmundsdottir AS, Sigmundsdottir H, Sigurgeirsson B et al. Is an epitope on keratin 17 a major target for autoreactive T lymphocytes in psoriasis? Clin Exp Immunol 1999; 117:580-6.
17. Jones DA, Yawalkar N, Suh K-Y et al. Identification of autogens in psoriasic plaques using expression cloning. J Invest Dermatol 2004; 123:93-100.
18. Sebbag M, Parry SL, Brennan FM, Feldmann M. Cytokine stimulation of T lymphocytes regulates their capacity to induce monocyte production of tumor necrosis factor-alpha, but not interleukin-10: possible relevance to pathophysiology of rheumatoid arthritis. Eur J Immunol 1997; 27:624-32.
19. Geginat J, Campagnaro S, Sallusto F, Lanzavecchia A. TCR-independent proliferation and differentiation of human CD4+ T cell subsets induced by cytokines. Adv Exp Med Biol 2002; 512:107-12.
20. Murali-Krishna K, Lau LL, Sambhara S et al. Persistence of memory CD8 T cells in MHC class I-deficient mice. Science 1999; 286:1377-81.
21. Swain SL, Hu H, Huston G. Class II-independent generation of CD4 memory T cells from effectors. Science 1999; 286:1381-3.
22. Bata-Csorgo Z, Hammerberg C, Voorhees JJ, Cooper KD. Kinetics and regulation of human keratinocyte stem cell growth in short-term primary ex vivo culture: cooperative growth factors from psoriatic lesional T lymphocytes stimulate proliferation among psoriatic uninvolved, but not normal, stem keratinocytes. J Clin Invest 1995; 95:317-27.
23. Jackson M, Howie SE, Weller R et al. Psoriatic keratinocytes show reduced IRF-1 and STAT-1α activation in response to gamma-IFN. FASEB J 1999; 13:495-502.
24. Chen SH, Arany I, Apisarnthanarax N et al. Response of keratinocytes from normal and psoriatic epidermis to interferon-gamma differs in the expression of zinc-alpha (2)-glycoprotein and cathepsin D. FASEB J 2000; 14:565-71.
25. Nickoloff BJ, Wrone-Smith T, Bonish B, Porcelli SA. Response of murine and normal human skin to injection of allogeneic blood-derived psoriatic immunocytes: detection of T cells expressing receptors typically present on natural killer cells, including CD94, CD158, and CD161. Arch Dermatol 1999; 135:546-52.
26. Bonish B, Jullien D, Dutronc Y et al. Overexpression of CD1d by keratinocytes in psoriasis and CD1d-dependent IFN-(gamma) production by NK-T cells. J Immunol 2000; 165:4076-85.
27. Gilhar Y, Ullmann H, Kerner B et al. Psoriasis is mediated by a cutaneous defect triggered by activated immunocytes: induction of psoriasis by cells with natural killer receptors. J Invest Dermatol 2002; 119:384-91.
28. Boyman O, Hefti HP, Conrad C et al. Spontaneous development of psoriasis in a new animal model shows an essential role for resident T cells and tumor necrosis factor-α. J Exp Med 2004; 199:731-6.
29. Cerwenka A, Lanier LL. Natural killer cells, viruses and cancer. Nat Rev Immunol 2001; 1:41-9.
30. Bata-Csorgo Z, Hammerberg C, Voorhees JJ, Cooper KD. Flow cytometric identification of proliferative subpopulations within normal human epidermis and the localization of the primary hyperproliferative population in psoriasis. J Exp Med 1993; 178:1271-81.
31. McKay IA, Leigh IM. Altered keratinocyte growth and differentiation in psoriasis. In: Pathogenic Aspects of Psoriasis. Clinics in Dermatology (Van de Kerkhof PCM, Bos JD, eds). 1995: 105-14.
32. Wrone-Smith T, Mitra RS, Thompson CB et al. Keratinocytes derived from psoriatic plaques are resistant to apoptosis compared with normal skin. Am J Pathol 1997; 151:1321-9.
33. Barker JN, Mitra RS, Griffiths CE et al. Keratinocytes as initiators of inflammation. Lancet 1991; 337:211-14.
34. Chu AC, Morris JF. The keratinocyte. In: Skin Immune System: Cutaneous Immunology and Clinical Immunodermatology (Bos JD, ed.), 3rd edn. Boca Raton, FL: CRC Press, 2005: 77-99.
35. Chang EY, Hammerberg C, Fisher G et al. T-cell activation is potentiated by cytokines released by lesional psoriatic, but not normal, epidermis. Arch Dermatol 1992; 128:1479-85.
36. Jablonska S. Immunological mechanisms in psoriasis: role of polymorphonuclear leukocytes. In: Psoriasis (Farber EM, Nall L, Morhenn V, Jacobs PH, eds). New York: Elsevier, 1986: 131-7.
37. Toichi E, Tachibana T, Furukawa F. Rapid improvement of psoriasis vulgaris during drug-induced agranulocytosis. J Am Acad Dermatol 2000; 43:391-5.
38. Rogalski C, Meyer-Hoffert U, Proksch E, Wiedow O. Human leukocyte elastase induces keratinocyte proliferation in vitro and in vivo. J Invest Dermatol 2002; 118:49-54.
39. Wilson SB, Delovitch TL. Janus-like role of regulatory iNKT cells in autoimmune disease and tumour immunity. Nat Rev Immunol 2003; 3:211-22.
40. Cameron AL, Kirby B, Fei W, Griffiths CEM. Natural killer and natural killer-T cells in psoriasis. Arch Dermatol Res 2002; 294:363-9.
41. Van der Vliet HJJ, Von Blomberg BME, Nishi N et al. Circulating Vα24+ Vβ11+ NKT cell numbers are decreased in a wide variety of diseases that are characterized by autoreactive tissue damage. Clin Immunol 2001; 100:144-8.
42. Teunissen MBM. Langerhans cells and other skin dendritic cells. In: Skin Immune System: Cutaneous Immunology and Clinical Immunodermatology (Bos JD, ed.), 3rd edn; Boca Raton, FL: CRC Press, 2005: 123-82.
43. Steinman RM, Hawiger D, Nussenzweig MC. Tolerogenic dendritic cells. Annu Rev Immunol 2003; 21:685-711.
44. Gallucci S, Lolkema M, Matzinger P. Natural adjuvants: endogenous activators of dendritic cells. Nat Med 1999; 5:1249-55.
45. Taniguchi M, Seino K, Nakayama T. The NKT cell system: bridging innate and acquired immunity. Nat Immunol 2003; 4:1164-5.
46. Abrams JR, Kelley SL, Hayes E et al. Blockade of T lymphocyte costimulation with cytotoxic T lymphocyte-associated antigen 4-immunoglobulin (CTLA4Ig) reverses the cellular pathology of psoriatic plaques, including the activation of keratinocytes, dendritic cells, and endothelial cells. J Exp Med 2000; 192:681-93.
47. Nickoloff BJ, Karabin GD, Barker JN et al. Cellular localization of interleukin-8 and its inducer, tumor necrosis factor-alpha in psoriasis. Am J Pathol 1991; 138:129-40.
48. Zhou X, Krueger JG, Kao M-CJ et al. Novel mechanism of T-cell and dendritic cell activation revealed by profiling of psoriasis on the 63,100-element oligonucleotide array. Physiol Genomics 2003; 13:69-78.
49. Pasch MC, Bos JD, Asghar SS. Activation of complement in psoriasis. Clin Exp Dermatol 1998; 23:189-92.
50. Asghar SS, Pasch MC. Complement as a promiscuous signal transduction device. Lab Invest 1998; 78:1203-25.
51. Ong PY, Ohtake T, Brandt C et al. Endogenous antimicrobial peptides and skin infections in atopic dermatitis. N Engl J Med 2002; 347:1151-60
52. Nomura I, Goleva E, Howell MD et al. Cytokine milieu of atopic dermatitis, as compared to psoriasis, skin prevents induction of innate immune response genes. J Immunol 2003; 171:3262-9.
53. Oppenheim JJ, Biragyn A, Kwak LW, Yang D. Roles of antimicrobial peptides such as defensins in innate and adaptive immunity. Ann Rheum Dis 2003; 62 (Suppl. 2): ii17-ii21.
54. Baker BS, Ovigne JM, Powles AV et al. Normal keratinocytes express Toll-like receptors (TLRs) 1, 2 and 5: modulation of TLR expression in chronic plaque psoriasis. Br J Dermatol 2003; 148:670-9.
55. Curry JL, Qin JZ, Bonish B et al. Innate immune-related receptors in normal and psoriatic skin. Arch Pathol Lab Med 2003; 127:178-86.
56. Bonifati C, Ameglio F. Cytokines in psoriasis. Int J Dermatol 1999; 38:241-51.
57. Ritchlin C, Haas-Smith SA, Hicks D et al. Patterns of cytokine production in psoriatic synovium. J Rheumatol 1998; 25:1544-52.
58. Victor FC, Gottlieb AB, Menter A. Changing paradigms in dermatology: tumor necrosis factor alpha (TNF-α) blockade in psoriasis and psoriatic arthritis. Clin Dermatol 2003; 21:392-7.
59. Ideker T. A systems approach to discovering signaling and regulatory pathways - or, how to digest large interaction networks into relevant pieces. Adv Exp Med Biol 2004; 547:21-30.
60. Cookson WOCM, Bowcock AC, Harper JI, Moffatt MF. The immunogenetics of inflammatory skin disease. In: Skin Immune System: Cutaneous Immunology and Clinical Immunodermatology (Bos JD, ed.), 3rd edn. Boca Raton, FL: CRC Press, 2005: 55-73.
61. Hohler T, Kruger A, Schneider PM et al. A TNF-alpha promoter polymorphism is associated with juvenile onset psoriasis and psoriatic arthritis. J Invest Dermatol 1997; 109:562-5.
62. Young HS, Summers AM, Bhushan M et al. Single-nucleotide polymorphisms of vascular endothelial growth factor in psoriasis of early onset. J Invest Dermatol 2004; 122:209-15.
63. Reich K, Mössner R, König IR et al. Promoter polymorphisms of the genes encoding tumor necrosis factor-α and interleukin-1β are associated with different subtypes of psoriasis characterized by early and late disease onset. J Invest Dermatol 2002; 118:155-63.
64. Donn RP, Plant D, Jury F et al. Macrophage migration inhibitory factor gene polymorphism is associated with psoriasis. J Invest Dermatol 2004; 113:484-7.
65. Foerster J, Nolte I, Schweiger S et al. Evaluation of the IRF-2 gene as a candidate for PSORS3. J Invest Dermatol 2004; 122:61-4.
66. Zhang X-J, He P-P, Wang Z-X et al. Evidence for a major psoriasis susceptibility locus at 6p21 (PSORS1) and a novel candidate region at 4q31 by genome-wide scan in Chinese hans. J Invest Derm 2002; 119:1361-6.
67. Karason A, Gudjonsson JE, Upmanyu R et al. A susceptibility gene for psoriatic arthritis maps to chromosome 16p: evidence for imprinting. Am J Hum Genet 2003; 72:125-31.